CID4 support will help Fort Collins-based KromaTiD launch innovative new products for detecting mutations that cause diseases such as cancer.
Aurora, CO June 11, 2012 – The Colorado Institute for Drug, Device and Diagnostic Development (CID4), a 501(c)(3) not-for-profit entity focused on advancing the Colorado life science ecosystem through company creation and job growth, has selected Fort Collins, Colorado based KromaTiD, Inc. to receive investment and operational support services. CID4’s support will help KromaTiD develop and bring to market next generation tools for identifying diseasecausing mutations.
“KromaTiD’s novel technology provides an exciting and important new tool to researchers and clinicians to detect unique changes in DNA, allowing them to detect various diseases quickly and accurately,” said Lauren Costantini, Ph.D., Vice President of Therapeutics and Device Development at CID4. “CID4’s capital and management resources will assist with the initial launch of this groundbreaking research tool, and allow KromaTiD to accelerate the development of clinical diagnostics.”
KromaTiD’s proprietary technology enables the imaging of individual strands within a chromosome, giving researchers and geneticists the unique ability to detect inverted DNA segments (inversions). Chromosomal inversions, which can be inherited or caused by ionizing radiation or mutagens, are genetic abnormalities known to be associated with cancers and developmental disorders.
However, because inversions occur within individual chromosomes, they have been difficult or impossible to detect by conventional imaging, array or sequencing methods. KromaTiD’s technology represents the first genome-wide inversion discovery and detection platform. The company’s research tools increase the resolution of inversion detection by at least 10-fold over current approaches, enabling new areas of disease research and ultimately a new class of clinical diagnostic tests.
“KromaTiD is an outstanding example of the innovative life science companies that are driving economic development in Colorado, and we are pleased to be able to add them to our portfolio,” said Kevin M. Smith, President and CEO of CID4.
“KromaTiD’s inversion discovery and detection technology has been in beta testing since late 2011. Now with our partnership with CID4, we are excited to begin our product launch providing these unique tools to biomedical researchers worldwide,” said Christopher Tompkins, Ph.D., President and CEO of KromaTiD. “Perhaps most exciting is that our platform has applications far beyond just detecting a single type of mutation and is truly a next generation approach to chromosome imaging and diagnostic testing.”
Based in Fort Collins, Colorado, KromaTiD, Inc. develops new chromosome imaging and analysis products for biomedical research and diagnostic medical testing. The company’s first products – custom kits and reagents for the discovery and detection of chromosomal inversions – are launching to selected researchers in 2012. For more information visit
About the Colorado Institute for Drug, Device and Diagnostic Development
Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee.
For more information visit http://CID4.com.
For more information, contact:
Kevin M. Smith
President & CEO
President & CEO